Methotrexate for treatment of atopic dermatitis in children and adolescents
| Autor: | Sarah E. Hill, Anthony Yung, Marius Rademaker, Maneka Deo |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty Adolescent Nausea Dermatology Dermatitis Atopic Medicine Humans Adverse effect Child Retrospective Studies business.industry Dermatology department Retrospective cohort study Mean age Atopic dermatitis medicine.disease Methotrexate Tolerability Child Preschool Female medicine.symptom business Immunosuppressive Agents medicine.drug |
| Zdroj: | International journal of dermatology. 53(8) |
| ISSN: | 1365-4632 |
| Popis: | Background: Low-dose methotrexate is becoming established as a second-line treatment for atopic eczema in the adult population, but there has been a paucity of data to support its use for this indication in the pediatric population. Methods: A retrospective review was undertaken of patients aged 18 years and under started on methotrexate between January 2005 and April 2010, at a hospital-based dermatology department in New Zealand. Results: Thirty-one patients (17 females, mean age 10 years, range 3-18 years) were reviewed. Methotrexate was found to be effective or very effective in 75% and ineffective in 25%. The mean duration of treatment for those who responded to methotrexate was 14 months (range 2-38 months), 74% of patients were still on treatment at the time of last review. The most common adverse effect was minor nausea in four patients (14%) and non-significant elevation of liver enzymes (four patients). No serious adverse effects were noted. Conclusion: In our experience, methotrexate has a good safety/tolerability profile when used in low dose for the treatment of atopic dermatitis in children and adolescents and appears to be effective. Formal comparative studies are needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text